On July 17, 2024, Rennova Health, Inc., a Delaware-based healthcare services provider, filed a Schedule 13D with the SEC, disclosing a significant stake in FOXO Technologies Inc. Rennova now beneficially owns 1,023,629 shares of FOXO Technologies' Class A Common Stock, representing 7.63% of the company, based on the number of shares outstanding as of June 27, 2024. This ownership stake resulted from a Stock Exchange Agreement where Rennova exchanged its equity interest in Myrtle Recovery Centers, Inc. for $500,000 worth of FOXO Technologies' stock at a volume-weighted average price of $0.23 per share. Additionally, Rennova entered into a separate agreement to exchange its equity interest in Rennova Community Health, Inc. for $20 million of convertible preferred stock in FOXO Technologies, subject to stockholder approvals. If this second transaction...Show More

On July 17, 2024, Rennova Health, Inc., a Delaware-based healthcare services provider, filed a Schedule 13D with the SEC, disclosing a significant stake in FOXO Technologies Inc. Rennova now beneficially owns 1,023,629 shares of FOXO Technologies' Class A Common Stock, representing 7.63% of the company, based on the number of shares outstanding as of June 27, 2024. This ownership stake resulted from a Stock Exchange Agreement where Rennova exchanged its equity interest in Myrtle Recovery Centers, Inc. for $500,000 worth of FOXO Technologies' stock at a volume-weighted average price of $0.23 per share. Additionally, Rennova entered into a separate agreement to exchange its equity interest in Rennova Community Health, Inc. for $20 million of convertible preferred stock in FOXO Technologies, subject to stockholder approvals. If this second transaction is completed, Rennova is expected to become the controlling shareholder of FOXO Technologies. The agreements also involve potential changes to FOXO's Board of Directors, with Rennova proposing five directors, including two current FOXO directors. The filing indicates that Rennova may engage in discussions with FOXO's management or Board of Directors regarding potential extraordinary corporate transactions.